Posted by Michael Wonder on 06 Jul 2016
Saskatchewan includes Lemtrada (alemtuzumab) on MS Drugs Program for eligible patients
5 July 2016 - Unique treatment delivered in only two cycles one year apart.
Sanofi Genzyme is pleased to announce that the Government of Saskatchewan has added Lemtrada (alemtuzumab) to the province's MS Drugs Program for eligible people living with relapsing-remitting multiple sclerosis (RRMS).
Saskatchewan is one of the first provinces among pan-Canadian Pharmaceutical Alliance (pCPA) members to provide coverage. The province of Québec included Lemtrada on its provincial formulary in 2014 under "Médicament d'exception" as second-line treatment for people living with RRMS.
